200 related articles for article (PubMed ID: 16648296)
41. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
[TBL] [Abstract][Full Text] [Related]
42. Insulin-like growth factor-I and bone mineral density.
Collins D; Woods A; Herd R; Blake G; Fogelman I; Wheeler M; Swaminathan R
Bone; 1998 Jul; 23(1):13-6. PubMed ID: 9662125
[TBL] [Abstract][Full Text] [Related]
43. Nmp4/CIZ suppresses parathyroid hormone-induced increases in trabecular bone.
Robling AG; Childress P; Yu J; Cotte J; Heller A; Philip BK; Bidwell JP
J Cell Physiol; 2009 Jun; 219(3):734-43. PubMed ID: 19189321
[TBL] [Abstract][Full Text] [Related]
44. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor.
Kulkarni NH; Wei T; Kumar A; Dow ER; Stewart TR; Shou J; N'cho M; Sterchi DL; Gitter BD; Higgs RE; Halladay DL; Engler TA; Martin TJ; Bryant HU; Ma YL; Onyia JE
J Cell Biochem; 2007 Dec; 102(6):1504-18. PubMed ID: 17520664
[TBL] [Abstract][Full Text] [Related]
45. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats.
Watson P; Lazowski D; Han V; Fraher L; Steer B; Hodsman A
Bone; 1995 Mar; 16(3):357-65. PubMed ID: 7786639
[TBL] [Abstract][Full Text] [Related]
46. Insulin like growth factor-I: a critical mediator of the skeletal response to parathyroid hormone.
Bikle DD; Wang Y
Curr Mol Pharmacol; 2012 Jun; 5(2):135-42. PubMed ID: 21787292
[TBL] [Abstract][Full Text] [Related]
47. Fibroblast Growth Factor Receptor 3 Deficiency Does Not Impair the Osteoanabolic Action of Parathyroid Hormone on Mice.
Xie Y; Yi L; Weng T; Huang J; Luo F; Jiang W; Xian CJ; Du X; Chen L
Int J Biol Sci; 2016; 12(8):990-9. PubMed ID: 27489502
[TBL] [Abstract][Full Text] [Related]
48. PTH ameliorates acidosis-induced adverse effects in skeletal growth centers: the PTH-IGF-I axis.
Green J; Goldberg R; Maor G
Kidney Int; 2003 Feb; 63(2):487-500. PubMed ID: 12631114
[TBL] [Abstract][Full Text] [Related]
49. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
Wang L; Quarles LD; Spurney RF
J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
[TBL] [Abstract][Full Text] [Related]
50. Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms.
Mohan S; Richman C; Guo R; Amaar Y; Donahue LR; Wergedal J; Baylink DJ
Endocrinology; 2003 Mar; 144(3):929-36. PubMed ID: 12586770
[TBL] [Abstract][Full Text] [Related]
51. RAGE supports parathyroid hormone-induced gains in femoral trabecular bone.
Philip BK; Childress PJ; Robling AG; Heller A; Nawroth PP; Bierhaus A; Bidwell JP
Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E714-25. PubMed ID: 20028966
[TBL] [Abstract][Full Text] [Related]
52. DMP-1-mediated Ghr gene recombination compromises skeletal development and impairs skeletal response to intermittent PTH.
Liu Z; Kennedy OD; Cardoso L; Basta-Pljakic J; Partridge NC; Schaffler MB; Rosen CJ; Yakar S
FASEB J; 2016 Feb; 30(2):635-52. PubMed ID: 26481310
[TBL] [Abstract][Full Text] [Related]
53. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
Wang L; Liu S; Quarles LD; Spurney RF
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
[TBL] [Abstract][Full Text] [Related]
54. Short-term intermittent PTH 1-34 administration enhances bone formation in SCID/Beige mice.
Sheehan S; Muthusamy A; Paul E; Sikes RA; Gomes RR
Endocr J; 2010; 57(5):373-82. PubMed ID: 20139633
[TBL] [Abstract][Full Text] [Related]
55. Treatment with N- and C-terminal peptides of parathyroid hormone-related protein partly compensate the skeletal abnormalities in IGF-I deficient mice.
Rodríguez-de la Rosa L; López-Herradón A; Portal-Núñez S; Murillo-Cuesta S; Lozano D; Cediel R; Varela-Nieto I; Esbrit P
PLoS One; 2014; 9(2):e87536. PubMed ID: 24503961
[TBL] [Abstract][Full Text] [Related]
56. The anabolic response to parathyroid hormone is augmented in Rac2 knockout mice.
Kawano T; Troiano N; Adams DJ; Wu JJ; Sun BH; Insogna K
Endocrinology; 2008 Aug; 149(8):4009-15. PubMed ID: 18467443
[TBL] [Abstract][Full Text] [Related]
57. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice.
DeMambro VE; Clemmons DR; Horton LG; Bouxsein ML; Wood TL; Beamer WG; Canalis E; Rosen CJ
Endocrinology; 2008 May; 149(5):2051-61. PubMed ID: 18276763
[TBL] [Abstract][Full Text] [Related]
58. Deficiency of the insulin-like growth factor-binding protein acid-labile subunit (ALS) of the circulating ternary complex in children with short stature.
Domené HM; Scaglia PA; Jasper HG
Pediatr Endocrinol Rev; 2010 Jun; 7(4):339-46. PubMed ID: 20679994
[TBL] [Abstract][Full Text] [Related]
59. beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice.
Bouxsein ML; Pierroz DD; Glatt V; Goddard DS; Cavat F; Rizzoli R; Ferrari SL
J Bone Miner Res; 2005 Apr; 20(4):635-43. PubMed ID: 15765183
[TBL] [Abstract][Full Text] [Related]
60. Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts.
Hilal G; Massicotte F; Martel-Pelletier J; Fernandes JC; Pelletier JP; Lajeunesse D
J Bone Miner Res; 2001 Apr; 16(4):713-21. PubMed ID: 11315999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
